BRPI1014922A2 - métodos e composições para tratar doenças de pele associadas com hiper-reatividade vascular - Google Patents

métodos e composições para tratar doenças de pele associadas com hiper-reatividade vascular

Info

Publication number
BRPI1014922A2
BRPI1014922A2 BRPI1014922A BRPI1014922A BRPI1014922A2 BR PI1014922 A2 BRPI1014922 A2 BR PI1014922A2 BR PI1014922 A BRPI1014922 A BR PI1014922A BR PI1014922 A BRPI1014922 A BR PI1014922A BR PI1014922 A2 BRPI1014922 A2 BR PI1014922A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
diseases associated
skin diseases
treating skin
Prior art date
Application number
BRPI1014922A
Other languages
English (en)
Inventor
Alice Du
Connie L Ho
Dan Browne
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of BRPI1014922A2 publication Critical patent/BRPI1014922A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24069Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
BRPI1014922A 2009-04-01 2010-03-30 métodos e composições para tratar doenças de pele associadas com hiper-reatividade vascular BRPI1014922A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16570109P 2009-04-01 2009-04-01
PCT/US2010/029183 WO2010114828A1 (en) 2009-04-01 2010-03-30 Methods and compositions for treating skin conditions associated with vascular hyper-reactivity

Publications (1)

Publication Number Publication Date
BRPI1014922A2 true BRPI1014922A2 (pt) 2016-04-19

Family

ID=42828661

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014922A BRPI1014922A2 (pt) 2009-04-01 2010-03-30 métodos e composições para tratar doenças de pele associadas com hiper-reatividade vascular

Country Status (12)

Country Link
US (3) US20120148562A1 (pt)
EP (1) EP2413947B1 (pt)
JP (2) JP6140445B2 (pt)
KR (1) KR101959234B1 (pt)
BR (1) BRPI1014922A2 (pt)
CA (1) CA2757449A1 (pt)
CY (1) CY1123249T1 (pt)
DK (1) DK2413947T3 (pt)
ES (1) ES2804328T3 (pt)
MX (1) MX2011010335A (pt)
PT (1) PT2413947T (pt)
WO (1) WO2010114828A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120546A2 (en) 2004-03-03 2005-12-22 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP2008531732A (ja) 2005-03-03 2008-08-14 ルバンス セラピュティックス インク. ボツリヌス毒素の局所塗布及び経皮送達のための組成物及び方法
EP2413947B1 (en) * 2009-04-01 2020-04-29 Revance Therapeutics, Inc. Methods and compositions for treating skin conditions associated with vascular hyper-reactivity
JP5454722B2 (ja) * 2011-11-30 2014-03-26 株式会社リコー プロジェクタ、表示装置、方法およびプログラム
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2836193B1 (en) 2012-04-13 2018-01-31 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (ii)
ES2612237T3 (es) 2013-03-22 2017-05-12 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, membranas de mucosas y/o uñas
WO2016092365A1 (en) 2014-12-08 2016-06-16 JJSK R&D Pte Ltd Carrier molecule compositions and related methods
ES2755815T3 (es) 2016-09-13 2020-04-23 Allergan Inc Composiciones de toxina de Clostridium no proteicas estabilizadas
WO2020010171A1 (en) * 2018-07-06 2020-01-09 Elastogenesis, Llc Dermal compositions and methods of use
EP4003906A4 (en) * 2019-07-30 2024-03-06 Academia Sinica PEPTIDE-LOADED CARRIER SYSTEMS AND USES THEREOF

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
US20040220100A1 (en) 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
EP2272340B1 (en) * 2002-08-19 2018-03-14 Ira Sanders Botulinum toxin
US7666435B2 (en) * 2002-08-19 2010-02-23 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
US7479133B2 (en) * 2003-06-30 2009-01-20 Johnson & Johnson Consumer Companies, Inc. Methods of treating acne and rosacea with galvanic generated electricity
US8486374B2 (en) * 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
LT2985039T (lt) 2004-03-03 2018-11-12 Revance Therapeutics, Inc. Botulino toksinų vietinis taikymas ir jų įvedimas per odą
US20050214325A1 (en) * 2004-03-26 2005-09-29 Vvii Newco 2003, Inc. Compositions and methods to increase the effect of a neurotoxin treatment
JP2008531732A (ja) * 2005-03-03 2008-08-14 ルバンス セラピュティックス インク. ボツリヌス毒素の局所塗布及び経皮送達のための組成物及び方法
US20070178121A1 (en) * 2006-01-27 2007-08-02 Allergan, Inc. Methods for enhancing skin treatments
KR20090096735A (ko) * 2006-12-29 2009-09-14 레반스 테라퓨틱스, 아이엔씨. Hiv-tat로부터 유래된 폴리펩티드 단편에 의해 안정화된 보툴리눔 독소의 국소 적용 및 경피 전달용 조성물 및 방법
WO2008082885A2 (en) 2006-12-29 2008-07-10 Revance Therapeutics, Inc. Transport molecules using reverse sequence hiv-tat polypeptides
HUE031136T2 (en) 2007-07-26 2017-07-28 Revance Therapeutics Inc Antimicrobial peptide and preparations
EP2413947B1 (en) * 2009-04-01 2020-04-29 Revance Therapeutics, Inc. Methods and compositions for treating skin conditions associated with vascular hyper-reactivity

Also Published As

Publication number Publication date
KR101959234B1 (ko) 2019-03-18
JP2012522786A (ja) 2012-09-27
CA2757449A1 (en) 2010-10-07
US20220347275A1 (en) 2022-11-03
US20120148562A1 (en) 2012-06-14
PT2413947T (pt) 2020-05-28
KR20120027170A (ko) 2012-03-21
MX2011010335A (es) 2012-01-12
JP6140445B2 (ja) 2017-05-31
EP2413947A4 (en) 2014-02-12
CY1123249T1 (el) 2021-10-29
WO2010114828A1 (en) 2010-10-07
EP2413947B1 (en) 2020-04-29
EP2413947A1 (en) 2012-02-08
ES2804328T3 (es) 2021-02-05
JP2017081997A (ja) 2017-05-18
DK2413947T3 (da) 2020-06-02
US20170136105A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
BRPI1014922A2 (pt) métodos e composições para tratar doenças de pele associadas com hiper-reatividade vascular
BR112012031117A2 (pt) método para tratamento antienvelhecimento de pele e kit para tratamento antienvelhecimento de pele
IL226127A0 (en) A compound containing hydrolyzed proteins and an oligosaccharide for the treatment of skin diseases
BR112013002644A2 (pt) método de enxertia de pele e método de tratamento de vitiligo
BR112012004979A2 (pt) composições para o tratamento de semente e métodos
BRPI0910874A2 (pt) composições e métodos para cuidado da pele
BRPI0923534A2 (pt) composição e método para tratamento de doenças de pele
BR112013007678A2 (pt) método para tratamento de doenças alérgicas
BR112013002642A2 (pt) método de preparo de um enxerto de pele e método de aplicação de enxerto de pele
EP2655334A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
BRPI0908087A2 (pt) Composições e métodos para implante de tecido adipose e produtos de tecido adiposo
BR112013018469A2 (pt) dispositivos e métodos para tratamento de tecidos
IL207360A0 (en) Methods of diagnosing and treating parp - mediated diseases
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BR112013011730A2 (pt) composição de oligossacarídeos para tratar doenças da pele
EP2432462A4 (en) OXYGEN PROCEDURE AND COMPOSITIONS FOR THE TREATMENT OF MAMMALIAN DISEASES
BRPI1008717A2 (pt) artigos e métodos de tratar condições vasculares.
BR112014012753A2 (pt) composição para pele e método de hidratação da pele
BRPI1008564A2 (pt) métodos e composições para o dignóstico e tratamento de câncer
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
EP2497482A4 (en) COMPOSITION FOR PROPHYLAXIS AND TREATMENT OF INFLUENZA AVIRUSED INDUCED DISEASES
EP2544655A4 (en) COMPOSITIONS AND METHODS FOR TREATING SKIN
BRPI1006238A2 (pt) método para o tratamento pesticida de plantações e composição
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
EP2525814A4 (en) METHODS OF TREATING OR PREVENTING PERIODONTITIS AND PARODONTIST-RELATED DISEASES

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]